亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

医学 阿替唑单抗 结直肠癌 内科学 肿瘤科 临床终点 免疫疗法 丸(消化) 化疗 DNA错配修复 临床研究阶段 随机对照试验 临床试验 泌尿科 癌症 帕尼单抗 血管内皮生长因子 外科 胃肠病学 总体生存率 完全响应 耐受性
作者
Caio Max Sao Pedro Rocha Lima,Greg Yothers,Thomas J. George,Howard S. Höchster,Hanna Kelly Sanoff,Deirdre Jill Cohen,Katherine Adams Guthrie,Samuel A. Jacobs,Anwaar Saeed,Scott Kopetz,Linda H. Colangelo,Tanner J. Freeman,Scott Wesley Cole,Maged F. Khalil,Swapna Devanna,Dan Sayam Zuckerman,Theodore Sunki Hong,Norah Lynn Henry,Patricia A. Ganz,Charles David Blanke
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (29): 2824-2834 被引量:3
标识
DOI:10.1200/jco-25-03052
摘要

PURPOSE Immunotherapy for frontline mismatch repair–deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) is effective; however, nearly half of the patients treated with single-agent PD-1 therapy will progress within 12 months. Preclinical studies in CRC and clinical data from other cancers suggest that vascular endothelial growth factor inhibition and chemotherapy can synergize with PD-L1 inhibition. METHODS The NRG-GI004/SWOG-S1610 (COMMIT) three-arm prospective phase III open-label trial randomly assigned first-line dMMR/MSI-H mCRC patients (1:1:1) to either: mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-FU bolus 400 mg/m², and 46-hour infusional 5-FU 2,400 mg/m²)/bevacizumab (FFX/bev), or atezolizumab (atezo) monotherapy (840 mg IV once every 2 weeks), or the combination of FFX/bev/atezo. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Because of KEYNOTE 177 results, the FFX/bev arm was closed after 20 patients were enrolled. The study continued with atezo alone versus FFX/bev/atezo, with a revised sample size of 100 patients in the two remaining arms (120 patients across all three arms). RESULTS From November 2017 to March 2025, a total of 102 patients were enrolled in the three arms: FFX/bev: n = 20, atezo: n = 41, and FFX/bev/atezo: n = 41. At a median follow-up of 46 months for the two arms (median age: 63.3 years; 47.6% female; 23.2% BRAF V600E mutated), PFS of FFX/bev/atezo was superior to that of atezo (hazard ratio [HR], 0.439 [95% CI, 0.23 to 0.84]; P = .0103) and below the critical value of 0.0152. The objective response rate was 86.1% versus 46%, and the disease control rate at 12 months was 64.7% versus 32.4% in the FFX/bev/atezo arm compared with the atezo-only arm, respectively. Grade 3 or higher adverse events of any attribution occurred in 52 patients (atezo: 18; combination arm: 34). CONCLUSION The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小井盖完成签到 ,获得积分0
刚刚
1秒前
含蓄的芝麻完成签到,获得积分10
2秒前
陌陌完成签到 ,获得积分10
3秒前
菌菌的应助被郦稀采纳,获得30
6秒前
9秒前
煊陌完成签到 ,获得积分10
12秒前
xiaoyin完成签到 ,获得积分10
13秒前
14秒前
14秒前
Lifel完成签到,获得积分10
14秒前
21秒前
23秒前
A水暖五金批发张哥完成签到,获得积分10
23秒前
Ni完成签到 ,获得积分10
24秒前
云墨完成签到 ,获得积分10
24秒前
25秒前
椰子云发布了新的文献求助10
27秒前
学术雷锋发布了新的文献求助10
30秒前
Moon完成签到 ,获得积分10
34秒前
天真的乐驹完成签到 ,获得积分10
38秒前
李健的小迷弟的应助被郦稀采纳,获得10
38秒前
Moon关注了科研通微信公众号
38秒前
39秒前
乐康完成签到,获得积分10
39秒前
42秒前
复杂惜珊完成签到,获得积分10
49秒前
cx完成签到,获得积分10
54秒前
机灵伟诚完成签到,获得积分10
54秒前
学霸业的应助被纯情的阁采纳,获得10
56秒前
极限001的应助被纯情的阁采纳,获得50
56秒前
Maestro_S的应助被纯情的阁采纳,获得10
56秒前
Nikkie2411的应助被纯情的阁采纳,获得10
56秒前
59秒前
1分钟前
369ninja的应助被科研通管家采纳,获得10
1分钟前
丘比特的应助被科研通管家采纳,获得10
1分钟前
手打鱼丸完成签到 ,获得积分10
1分钟前
1分钟前
完美世界的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277